W
W. Lin
Researcher at Genentech
Publications - 18
Citations - 3794
W. Lin is an academic researcher from Genentech. The author has contributed to research in topics: Atezolizumab & Carboplatin. The author has an hindex of 9, co-authored 16 publications receiving 2234 citations.
Papers
More filters
Journal ArticleDOI
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn,Aaron S. Mansfield,Aleksandra Szczesna,Libor Havel,Maciej Krzakowski,Maximilian Hochmair,Florian Huemer,György Losonczy,Melissa Lynne Johnson,Makoto Nishio,Martin Reck,Tony Mok,S. Lam,David S. Shames,Juan Liu,Beiying Ding,Ariel Lopez-Chavez,F. Kabbinavar,W. Lin,Alan Sandler,Stephen V. Liu +20 more
TL;DR: The addition of atezolizumab to chemotherapy in the first‐line treatment of extensive‐stage small‐cell lung cancer resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
Journal ArticleDOI
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard Jack West,Michael McCleod,Maen A. Hussein,Alessandro Morabito,Achim Rittmeyer,Henry Jacob Conter,Hans-Georg Kopp,Davey B. Daniel,Steven L. McCune,Tarek Mekhail,Alona Zer,Niels Reinmuth,Ahad Sadiq,Alan Sandler,W. Lin,Tania Ochi Lohmann,V. Archer,Lijia Wang,Marcin Kowanetz,Federico Cappuzzo +19 more
TL;DR: IMpower130 aimed to assess the efficacy and safety of atezolizumab plus chemotherapy versus chemotherapy alone as first-line therapy for non-squamous non-small-cell lung cancer and the intention-to-treat wild-type population.
Journal ArticleDOI
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Martin Reck,Tony Mok,Makoto Nishio,Robert M. Jotte,Federico Cappuzzo,Francisco Orlandi,Daniil Stroyakovskiy,Naoyuki Nogami,Delvys Rodriguez-Abreu,Denis Moro-Sibilot,Christian A. Thomas,Fabrice Barlesi,Gene Grant Finley,Anthony Lee,Shelley Coleman,Yu Deng,Marcin Kowanetz,Geetha Shankar,W. Lin,Mark A. Socinski,Tony Sk Mok +20 more
TL;DR: Improved overall survival with ABCP versus BCP was observed in patients with sensitising EGFR mutations, and overall survival in the intention-to-treat population, including EGFR-positive patients and patients with baseline liver metastases.
Journal ArticleDOI
OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC
Vassiliki A. Papadimitrakopoulou,Manuel Cobo,Rodolfo Bordoni,P. Dubray-Longeras,Zsuzsanna Szalai,Grigoriy Ursol,Silvia Novello,Francisco Orlandi,S. Ball,Jerome H. Goldschmidt,Rachel E. Sanborn,Tien Hoang,Diana Mendus,Yu Deng,Marcin Kowanetz,X. Wen,W. Lin,Alan Sandler,Makoto Nishio +18 more
Journal ArticleDOI
IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC
Frederico Cappuzzo,Michael McCleod,Maen A. Hussein,Alessandro Morabito,Achim Rittmeyer,Henry Jacob Conter,H.-G. Kopp,Davey B. Daniel,Steven L. McCune,Tarek Mekhail,Alona Zer,Niels Reinmuth,Ahad Sadiq,V. Archer,T. Ochi Lohmann,Lan Wang,Marcin Kowanetz,W. Lin,Alan Sandler,Howard West +19 more